8-K current report · filed Nov 10, 2026

CAPRICOR THERAPEUTICS, INC. (CAPR) 8-K Current Report: November 10, 2026

Item 2.02Item EX-99.1CAPR overview

Short answer

CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Capricor Therapeutics announced financial results for the quarter ended September 30, 2026.

CAPRICOR THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Capricor Therapeutics announced financial results for the quarter ended September 30, 2026
  • Investors should review the accompanying press release for quarterly financial figures and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Deramiocel BLA remains under FDA review, with PDUFA decision targeted for November 22, 2026
  • Major amendment narrows proposed indication to upper-limb impairment in DMD patients older than 9
  • HOPE-3 OLE showed 76% slower upper-limb decline after placebo patients switched to Deramiocel
  • Cash, restricted cash and marketable securities $198.5M, down from $318.1M at December 31, 2025
  • Nine-month operating expenses $124.4M and net loss $117.3M, reflecting pre-commercial and manufacturing scale-up costs

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CAPRICOR THERAPEUTICS, INC. 8-K filings

Get the next CAPR 8-K as it lands

Follow CAPR for push alerts, or ask the research agent what this filing means.